Sarcoma

Research Article

Cost-Effectiveness of Pazopanib in Advanced Soft Tissue Sarcoma in the United Kingdom

Table 4

Cost estimates used in the model.
EstimateCosts, Reference
Medications unit costs  
 Pazopanib, 200 mg tablet
  (no discount)		18.68British National Formulary [32]
 Pazopanib, 200 mg tablet
 (with discount)		16.35 
 Trabectedin (per mg)a1,366 
 Ifosfamide (per mg)0.04 
 Gemcitabine (per mg)0.14 
 Docetaxel (per mg)5.14 
 Lenograstim (per mg)238 
 Mesna (per mg)0.010 
Total costs of poststudy chemotherapy  
 Placebo11,493PALETTE, British National Formulary [32]
 Pazopanibb8,531NHS 2010-2011 Reference Costs [35]
Administration/dispensing  
 Pazopanib12.00NHS 2010-2011 Reference Costs [35]
 Ifosfamide 331.49 
 Trabectedin331.49 
 Gemcitabine plus docetaxel204.68 
Management costsc  
 Preprogression monthly
 cost		 92Judson et al. 2007 [36]
 Postprogression monthly
 cost		185 
Costs are capped after five cycles; bpoststudy costs are assumed to be the same for pazopanib, ifosfamide, trabectedin, and gemcitabine + docetaxel in the indirect comparison; ccosts are updated to 2010/11 prices; preprogression costs are assumed to be half of postprogression costs.